Literature DB >> 6980251

Bradykinin-mediated hypotension after infusion of plasma-protein fraction.

R F Van Rosevelt, J C Bakker, D M Sinclair, J Damen, J A Van Mourik.   

Abstract

In patients who required volume expansion during extracorporeal circulation, the plasma bradykinin concentration was monitored simultaneously with the mean arterial pressure during infusion of either albumin solution or PPF. The PKA content of the PPF and the albumin solution was 29 and 3 U/L, respectively, measured spectrophotometrically. In six patients receiving 250 ml of PPF, the mean arterial pressure decreased 22% to 54% within 1.5 min after infusion, whereas the plasma bradykinin concentration, measured by radioimmunoassay, increased significantly (p less than 0.0005) during the first minute. In six patients receiving 250 ml of 4% albumin solution, no blood pressure changes were found, and the plasma bradykinin concentration rose only slightly. In vitro, linear correlation (r = 0.94, p less than 0.0005) was observed between the level of PKA of 26 different lots of PPF and the concentrations of bradykinin that were generated in Hageman factor-deficient plasma after incubation with PPF. It is concluded that the hypotensive reactions observed after PPF infusion during extracorporeal circulation are caused by the PKA-induced bradykinin generation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6980251

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  3 in total

1.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

2.  Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting.

Authors:  Ayaka Fujita; Masatou Kitayama; Kazuyoshi Hirota
Journal:  J Anesth       Date:  2007-08-01       Impact factor: 2.078

3.  Development of an updated assay for prekallikrein activator in albumin and immunoglobulin therapeutics.

Authors:  Graham Roberts; Bernard Fox; Colin Longstaff
Journal:  Vox Sang       Date:  2020-09-28       Impact factor: 2.144

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.